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Introduction
Transforming growth factor-β (TGF-β) is a ubiquitous
cytokine that was originally identified as a factor able to
stimulate the transformation of certain fibroblast cell lines
[1]. It is now known that TGF-β is one of the most potent
secreted inhibitors of cell mitogenesis and has a critical
role in negatively regulating epithelial, hematopoietic,
and endothelial cell proliferation. Studies in animal
models of cancer indicate that TGF-β mediates tumor
suppression [2,3]. Several components of the TGF-β
signaling pathway, including SMADs 2 and 4 and the
TGF-β receptors type I and type II (TβRI and TβRII), are
downregulated or mutationally inactivated in human
cancers (reviewed in [4–6]). Furthermore, epidemiologi-
cal studies indicate that polymorphisms of elements of
the TGF-β signaling pathway influence the risk of devel-
oping breast cancer and colon cancer [7,8]. Together,
these studies indicate that TGF-β acts as a tumor sup-
Cdk2 = cyclin-dependent kinase-2; Cdk4 = cyclin-dependent kinase-4; DAPI = 4′,6′-diamidino-2-phenylindole; HMECs = primary human mammary
epithelial cells; PBS = phosphate-buffered saline; Rb = retinoblastoma tumor suppressor protein; TβRI and TβRII = TGF-β receptors type I and type
II; TGF-β = transforming growth factor-β.
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Abstract
Background: The transforming growth factor-β (TGF-β)
signaling pathway functions to prevent tumorigenesis, and loss
of sensitivity to TGF-β-mediated cell cycle arrest is nearly
ubiquitous among human cancers. Our previous studies
demonstrated that rapamycin potentiates TGF-β-induced cell
cycle arrest in nontransformed epithelial cells and partially
restores TGF-β-induced growth arrest of some human cancer
cell lines. Growth arrest correlated with increased binding of
p21 and p27 to cyclin-dependent kinase-2 (Cdk2), and
inhibition of Cdk2 kinase activity. However, it was unclear how
TGF-β caused increased binding of p21 and p27 to Cdk2.
Methods: Cell fractionation and immunofluorescence
microscopy experiments were performed to examine the effect
of TGF-β on the intracellular localization of Cdk2, p21, and
p27. Kinase assays were performed on cytoplasmic and
nuclear extracts to determine how TGF-β altered Cdk2 activity
in both subcellular compartments.
Results: In breast epithelial cells treatment with TGF-β induced
a decrease in nuclear Cdk2 concentrations and relocalization
of Cdk2 to the cytoplasm. Cdk2 relocalization to the cytoplasm
correlated with dephosphorylation of nuclear retinoblastoma
tumor suppressor protein and decreased nuclear Cdk2 activity.
In these epithelial cell lines, p21 and p27 were localized
primarily in the cytoplasm. Decreases in nuclear Cdk2
concentrations correlated with increased binding of Cdk2 to
cytoplasmic p21 and p27.
Conclusion: Cooperative growth arrest induced by treatment
with TGF-β + rapamycin causes inhibition of nuclear Cdk2
activity through multiple mechanisms, including Cdk2
relocalization to the cytoplasm, increased p27 and p21 binding
to Cdk2, and increased phosphorylation of nuclear Cdk2 on its
inhibitory site, Tyr15.
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pressor, but that this TGF-β function is abrogated in
cancers. Interestingly, many cancers still respond to
TGF-β by transcriptional activation of TGF-β-sensitive
genes, despite having lost sensitivity to the growth
inhibitory effects of TGF-β. These results might indicate
that the pathways through which TGF-β regulates cell
cycle progression and its other biological effects are at
least partly separable. If this is so, it might be possible to
specifically reactivate or potentiate TGF-β-induced
growth arrest in human cancers without altering other
TGF-β responses.
TGF-β induces cell cycle arrest through several interde-
pendent mechanisms, including the downregulation of c-
Myc [9,10], the inhibition of Cdk4 activity [11], the
inhibition of Cdk2 activity [12,13], and the inhibition of
E2F-dependent transcription [14–16]. The immunosup-
pressant rapamycin induces the arrest of cell proliferation
through mechanisms that overlap with the mechanisms of
TGF-β-mediated growth inhibition, including the downreg-
ulation of c-Myc [17], the inhibition of Cdk2 [18], and the
inhibition of E2F-dependent transcription [19], suggesting
that TGF-β and rapamycin might cooperate to induce cell
cycle arrest. Our previous studies indicated that
rapamycin potentiates the TGF-β-induced growth arrest of
nontransformed cells in culture, and largely restores the
TGF-β-mediated cell cycle arrest of epithelial cells trans-
formed by c-Myc and E2F1 [20]. Growth arrest induced
by TGF-β + rapamycin correlates well with increased
binding of p21 and p27 to Cdk2, and with inhibition of
Cdk2 activity. However, it was unclear from these studies
what the mechanisms were through which TGF-β and
rapamycin cooperated to increase p21 and p27 binding to
Cdk2 in cases where TGF-β + rapamycin did not affect
total concentrations of p21 or p27.
In the present studies we show that in several epithelial
cell lines p21 and p27 are localized predominantly to the
cytoplasm, whereas Cdk2 is present in both the nuclear
and cytoplasmic compartments. TGF-β, and to a greater
extent TGF-β + rapamycin, induce a decrease in nuclear
Cdk2 concentrations coincident with an increased binding
of cytoplasmic Cdk2 to cytoplasmic p21 and p27. We
show for the first time that TGF-β induces a change in
Cdk2 subcellular localization and inhibits nuclear Cdk2
activity. The decrease in nuclear Cdk2 concentrations and
activity coincides with the dephosphorylation of nuclear
nuclear retinoblastoma tumor suppressor protein (Rb) and
cell cycle arrest.
Materials and methods
Cell culture
HaCaT, MDA-MB-231, and NMuMG cells were cultured
as described previously [20]. Primary human mammary
epithelial cells (HMECs) were acquired from the Vander-
bilt-Ingram Cancer Center Breast Cell Repository. HMECs
were grown in Dulbecco’s modified Eagle’s medium:F12
medium (dilution 1:1) (Gibco-BRL, Grand Island, NY) sup-
plemented with 1% fetal bovine serum, 10 µg/ml ascorbic
acid, 2 nM β-estradiol, 35 µg/ml bovine pituitary extract,
1 ng/ml cholera toxin, 12.5 ng/ml epidermal growth factor,
0.1 mM ethanolamine, 0.1 mM phospho-ethanolamine,
1 µg/ml hydrocortisone, 1 µg/ml insulin, 0.2 mM L-gluta-
mine, 10 nM T3, 10 µg/ml transferrin, and 15 nM sodium
selenite. HaCaT, MDA-MB-231, and NMuMG cells were
plated 24 hours before treatment in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine
serum and 10 µg/ml insulin. HMECs were plated and
treated in the medium described above.
Preparation of cytoplasmic and nuclear cell extracts
Cytoplasmic and nuclear extracts were prepared with the
NE-PER kit (Pierce Biotechnology, Inc, Rockford, IL) in
accordance with the manufacturer’s instructions. The
protein concentrations of the extracts were determined
with the Bradford assay (Bio-Rad Laboratories, Hercules,
CA). Protein concentrations of extracts from cells sub-
jected to different treatments were normalized. In all cases
the cytoplasmic and nuclear extracts from a given cell
treatment correspond to protein from an equal number of
cells. HIRA (TUP1-like enhancer of split protein 1) was
used as a nuclear protein marker to follow the efficiency of
the fractionation procedure. HIRA is a protein previously
shown to exist exclusively in the nucleus and is a substrate
for Cdk2 phosphorylation [21]. In all of the extracts pre-
pared, c-Myc and Sp1 were also present exclusively in the
nuclear fractions (data not shown). c-Raf was used as a
marker for the cytoplasm. Tubulin was also present exclu-
sively in the cytoplasmic fractions, and except in the
HaCaT cells, actin was also present exclusively in the
cytoplasmic fractions (data not shown).
Immunoblotting and immune-complex kinase assays
Immunoblotting and immune-complex kinase assays were
performed as described previously [20]. The results of
kinase assays were revealed with a Fujifilm FLA-5000
PhosphoImager and quantified with Image Gauge version
3.4X software (Fujifilm Medical Systems, Inc, Alpharetta,
GA). Antibodies specific for Cdk2 (sc-163), p21
(sc-6246), Raf (sc-227), Sp1 (sc-59), cyclin E (sc-481),
and Cdk4 (sc-601) were purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA, USA). Antibodies
specific for Rb phosphorylated on Thr821 (44-582Z) and
Ser249/Thr252 (44-584Z) were from BioSource (Camarillo,
CA). Antibodies recognizing total Rb (554136) and p27
(554069) were obtained from BD Transduction Laborato-
ries (San Diego, CA). Dr Peter Adams (Fox Chase Cancer
Center, Philadelphia, PA) generously provided a mono-
clonal antibody against HIRA. Antibodies recognizing
Cdk2 phosphorylated on Thr160 (no. 2561) and Tyr15 (no.
9111) were obtained from Cell Signaling Technology, Inc
(Beverly, MA).Breast Cancer Research    Vol 6 No 2 Brown et al.
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Immunofluorescence and confocal immunofluorescence
microscopy
Subconfluent cells, grown on 22 mm2 glass cover slips
(VWR Scientific, Atlanta, GA), were treated for 24 h with
10 ng/ml TGF-β1. After treatment, cells were washed
once with phosphate-buffered saline (PBS) and fixed with
1% paraformaldehyde/PBS for 20 min at 25°C. Cells
were washed four times with PBS, permeabilized by incu-
bation with 0.2% Triton X-100 (in PBS) for 10 min at
25°C, then washed twice more with PBS. Non-specific
binding sites were blocked by incubating the cells for 2 h
with 5% goat serum in PBS. Cells were then incubated
with Cdk2 primary antibodies diluted in 5% serum/PBS
(dilution 1:200) for 1 h at 25°C, followed by four washes
with PBS. In control experiments Cdk2 staining was
blocked by using the immunizing peptide (sc-163P; Santa
Cruz Biotechnology, Inc, Santa Cruz, CA) at a 100-fold
molar excess over the antibody.
Cells were incubated for 1 h at 25°C with goat anti-rabbit
biotinylated secondary antibodies (Vector Laboratories,
Inc, Burlingame, CA) diluted 1:250 in 5% serum/PBS,
washed four times with PBS, and incubated with strepta-
vidin-conjugated Cy3 (Sigma, St Louis, MO) diluted in
5% serum/PBS (dilution 1:1000) for 1 h at 25°C. Cells
were washed four times with PBS, nuclei were counter-
stained by incubation with 1 mM 4′,6′-diamidino-2-
phenylindole (DAPI; Sigma) for 5 min at 25°C, and cells
were washed three times with PBS. Cover slips were
mounted on 25 mm × 75 mm microslides (Fisher Scien-
tific, Pittsburgh, PA) using AquaPolyMount (Polysciences,
Warrington, PA). Actin filaments were stained using
Texas Red-X phalloidin (Molecular Probes, Inc, Eugene,
OR) at a dilution of 1:200. Fluorescent images were cap-
tured with a Zeiss Axiophot upright microscope and a
Princeton Instruments cooled charge-coupled device
digital camera. Confocal images were captured with a
Zeiss LSM510 confocal microscope (Carl Zeiss
MicroImaging, Inc, Thornwood, NY).
Results
TGF-β β induces Cdk2 relocalization from the nucleus to
the cytoplasm
TGF-β1 and rapamycin cooperate to induce growth arrest
by increasing p21 and p27 binding to Cdk2, resulting in
Cdk2 inhibition [20]. We hypothesized that p21 and p27
binding to Cdk2 induced by TGF-β1 + rapamycin might
result from changes in the intracellular localization of p21
and p27 or Cdk2. To test this hypothesis, nontransformed
mouse mammary gland epithelial NMuMG cells, MDA-MB-
231 human mammary carcinoma cells, HMECs, or HaCaT
human keratinocytes were treated for 24 h with normal
growth medium, or medium containing 10 ng/ml TGF-β1
plus 100 nM rapamycin, and fractionated into cytoplasmic
and nuclear extracts. In agreement with our previous
observations [20], in parallel experiments the treatment of
NMuMG, MDA-MB-231, HaCaT, and HMECs with TGF-β
+ rapamycin for 24 h induced a potent cell cycle arrest in
3H-thymidine incorporation and sequential cell counting
assays (data not shown). The resulting extracts were ana-
lyzed by immunoblotting. c-Raf was used as a cytoplasmic
marker, and HIRA [21] was used as a nuclear marker. In
NMuMG cells, MDA-MB-231 cells, and HMECs, Cdk2
was distributed between the cytoplasmic and nuclear frac-
tions, but treatment with TGF-β1 + rapamycin resulted in a
selective decrease in nuclear Cdk2 concentrations
(Fig. 1a). Similar results were obtained with Balb/MK
mouse keratinocytes (data not shown).
Under the same conditions, TGF-β1 + rapamycin had no
effect on Cdk4 (Fig. 1a) or Cdc2 localization (data not
shown). In NMuMG cells and MDA-MB-231 cells, cyclin E
localization paralleled Cdk2 localization, suggesting that
effects of treatment on intracellular localization were spe-
cific for Cdk2 complexes. In HaCaT cells, TGF-β1 caused
a small decrease in nuclear Cdk2 concentrations,
rapamycin had no effect, but TGF-β1 + rapamycin
induced a larger decrease in nuclear Cdk2 concentrations
than TGF-β1 alone (Fig. 1a). Because we showed previ-
ously that TGF-β1 and rapamycin cooperate to induce cell
cycle arrest [20], these results are consistent with the idea
that decreases induced in nuclear Cdk2 concentrations
by TGF-β1 + rapamycin constitute a novel mechanism by
which TGF-β1 mediates cell cycle arrest.
To confirm the results of the cell fractionation experiments
we performed immunofluorescence microscopy studies.
As shown in Fig. 1b (left panel), Cdk2 was largely nuclear
in control NMuMG cells, but TGF-β1 induced a diffuse
localization of Cdk2 throughout the entire cell volume. No
staining was observed when the Cdk2 primary antibody
was omitted, or blocked with an excess of immunizing
peptide (data not shown). TGF-β1 + rapamycin induced
changes in Cdk2 localization similar to those induced by
TGF-β1 alone (data not shown); however, cells treated
with TGF-β1 + rapamycin were more rounded than
TGF-β1-treated cells, making it difficult to distinguish
between cytoplasmic and nuclear Cdk2 staining. In
HaCaT cells (Fig. 1b, right panel) Cdk2 was predomi-
nantly nuclear, but treatment with TGF-β1 induced a
diffuse localization of Cdk2 throughout the entire cell
volume, as observed in NMuMG cells. Similar results were
obtained in immunofluorescence microscopy experiments
employing HMECs (data not shown). The results in Fig. 1b
were confirmed by confocal immunofluorescence
microscopy (Fig. 1c and data not shown). These experi-
ments demonstrate that Cdk2 was localized to the
nucleus of untreated NMuMG cells, but that TGF-β1
induced the relocalization of Cdk2 throughout the entire
cell volume, as demarcated by cortical actin staining. In
HMECs (Fig. 1c, right panel) TGF-β1 treatment induced a
more cytoplasmic localization of Cdk2 with partial exclu-sion from the nucleus. Taken together, our results indicate
that TGF-β1, and to a greater extent TGF-β1 + rapamycin,
induced a partial relocalization of Cdk2 from the nucleus
to the cytoplasm.
Decreased nuclear Cdk2 concentrations correlate with
dephosphorylation of nuclear Rb
Cdk2 has several nuclear substrates whose phosphoryla-
tion is thought to play a role in cell cycle progression
[21–25]. We hypothesized that TGF-β1 + rapamycin-
induced decreases in nuclear Cdk2 concentrations might
result in cell cycle arrest through decreased phosphoryla-
tion of nuclear Cdk2 substrates. In particular, Rb is an
important Cdk2 substrate, and decreased phosphorylation
of nuclear Rb should inhibit E2F-dependent transcription
and induce cell cycle arrest. Thus, cytoplasmic Cdk2 relo-
calization induced by TGF-β1 + rapamycin could explain
the ability of TGF-β1 + rapamycin to inhibit E2F-depen-
dent transcription and induce growth arrest.
To test the hypothesis that Cdk2 relocalization induced by
TGF-β1 + rapamycin results in Rb dephosphorylation,
cytoplasmic and nuclear extracts were analyzed by
immunoblotting with phospho-specific and total Rb anti-
bodies. In untreated NMuMG cells, Rb was predominantly
nuclear and existed in two forms, a slower-migrating
hyperphosphorylated form and a faster-migrating hypo-
phosphorylated form (Fig. 2). In NMuMG cells treated with
TGF-β1 + rapamycin, Rb existed almost exclusively in the
hypophosphorylated form. To examine changes in the
phosphorylation status of individual Rb phosphorylation
sites we employed phosphorylation-site-specific antibod-
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Figure 1
TGF-β alters Cdk2 localization. (a) NMuMG, MDA-MB-231, primary human mammary epithelial (HMEC), or HaCaT cells were treated for 24 h with
normal growth medium (Cont.), 10 ng/ml TGF-β1 (T), 100 nM rapamycin (R), or a combination of both (T + R). The cells were subjected to
subcellular fractionation into nuclear (N) and cytoplasmic (C) extracts as described in Materials and Methods and the resulting fractions were
analyzed by immunoblotting with the indicated antibodies. HIRA served as a marker for the nucleus, and Raf was used as a marker for the
cytoplasm. (b) NMuMG cells (left panel) or HaCaT cells (right panel) were treated for 24 h with 10 ng/ml TGF-β1 and the cells were stained with
antibodies specific for Cdk2 (shown in green), and with 4′,6′-diamidino-2-phenylindole (DAPI; shown in red) as a nuclear stain, as described in
Materials and Methods. In the merged images, Cdk2 and DAPI staining are overlaid. (c) NMuMG cells (left panel) treated as in (b) were stained for
Cdk2 (green) and actin (red) and were imaged by confocal microscopy. HMECs (right panel) treated as in (b) were stained for Cdk2 (green) and
were imaged by confocal microscopy.ies against phospho-Rb(Thr821) and phospho-Rb(Ser249/
Thr252). Thr821 is phosphorylated in vitro preferentially by
cyclin E/cyclin A–Cdk2 complexes and phosphorylation at
this site inhibits E2F binding [26]. Ser249/Thr252 are phos-
phorylated in vitro preferentially by cyclin D1–Cdk4 com-
plexes, and the biological function of these
phosphorylation sites is unknown. In NMuMG cells, Rb
phosphorylated on Thr821 was observed primarily in the
cytoplasm and phosphorylation levels did not change sig-
nificantly with TGF-β1 + rapamycin treatment. Interest-
ingly, Rb phosphorylated on Ser249/Thr252 existed in both
the nucleus and cytoplasm of untreated NMuMG cells, but
was not observed in either compartment of NMuMG cells
treated with TGF-β1 + rapamycin.
In untreated MDA-MB-231 cells, both unphosphorylated
Rb and Rb phosphorylated on Thr821 and Ser249/Thr252
were observed in both the nuclear and cytoplasmic com-
partments. Strikingly, treatment with TGF-β1 + rapamycin
specifically decreased the phosphorylation of Rb at Thr821
and Ser249/Thr252 in the nuclear compartment but not in
the cytoplasm. In HMECs, TGF-β1 + rapamycin induced
the dephosphorylation of nuclear, but not cytoplasmic, Rb
at Thr821. In contrast, Rb phosphorylated on Ser249/Thr252
was observed primarily in the cytoplasm, and phosphoryla-
tion was minimally decreased by treatment with
TGF-β1 + rapamycin. In HaCaT cells, Rb was primarily
nuclear, whereas Rb phosphorylated on Thr821 was dis-
tributed evenly between the nucleus and the cytoplasm.
Rb phosphorylation on Ser249/Thr252 was not detected in
HaCaT cells. Importantly, TGF-β1 and rapamycin cooper-
ated to induce Rb dephosphorylation on Thr821 in both the
nucleus and the cytoplasm and resulted in a mobility shift
consistent with Rb dephosphorylation. Taken together,
these results indicate that TGF-β1 + rapamycin blocked
the phosphorylation of nuclear Rb in all cases, but only
blocked the phosphorylation of cytoplasmic Rb in specific
instances.
p21 and p27 are predominantly cytoplasmic in
mammary epithelial cells and human keratinocytes
Because TGF-β1 + rapamycin induced the cytoplasmic
relocalization of Cdk2 (Fig. 1), and our previous studies
[20] demonstrated that TGF-β1 and rapamycin cooperate
to induce p21 and p27 binding to Cdk2, we examined the
intracellular localization of p21 and p27. Immunoblot
analysis of the cytoplasmic and nuclear extracts demon-
strated that in NMuMG cells, MDA-MB-231 cells, and
HMECs, p27 was localized primarily to the cytoplasm of
both untreated cells and cells treated with
TGF-β1 + rapamycin (Fig. 3). The low concentrations of
nuclear p27 in NMuMG and HMECs was further
decreased by treatment with TGF-β + rapamycin. p27
expression was not detected in HaCaT cells. p21 expres-
sion was primarily cytoplasmic in the four cell lines exam-
ined in both untreated cells and cells treated with
TGF-β1 + rapamycin. TGF-β1 + rapamycin significantly
increased total p21 concentrations in both MDA-MB-231
and HaCaT cells without affecting p21 intracellular local-
ization. Taken together, the results in Figs 1 and 3 indicate
that TGF-β1 induces increased p21 and p27 concentra-
tions in the cytoplasm that correlate temporally with Cdk2
relocalization to this compartment.
Cytoplasmic relocalization of Cdk2 coincides with
increased Cdk2 binding to cytoplasmic p21 and p27
The hypothesis that the cytoplasmic localization of Cdk2
results in increased binding of Cdk2 to cytoplasmic p21
and p27 was tested by preparing cytoplasmic and nuclear
extracts from treated and untreated MDA-MB-231
(Fig. 4a) or NMuMG (Fig. 4b) cells. Treated cells were
subjected to subcellular fractionation and the fractions
were analyzed in Cdk2 coimmunoprecipitation experi-
ments. As expected, loss of Cdk2 from the nuclear frac-
tion of MDA-MB-231 cells after treatment with
TGF-β + rapamycin resulted in increased binding of Cdk2
to cytoplasmic p21 (Fig. 4a). p27 binding to Cdk2 was
Breast Cancer Research    Vol 6 No 2 Brown et al.
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Figure 2
TGF-β and rapamycin together induce the dephosphorylation of nuclear Rb. The cytoplasmic (C) and nuclear (N) extracts prepared in Fig. 1a were
analyzed by immunoblotting with antibodies specific for Rb phosphorylated on Thr821 (P-Rb(Thr821)), Rb phosphorylated on Ser249/Thr252 (P-
Rb(Ser249/Thr252)), and total Rb. Where two bands of total Rb are apparent, the upper band represents hyperphosphorylated Rb and the lower
band hypophosphorylated Rb. Cont., control; T + R, 10 ng/ml TGF-β1 plus 100 nM rapamycin; HMEC, primary human mammary epithelial cells.not detected in MDA-MB-231 cell extracts. In NMuMG
cells, treatment with TGF-β1 resulted in decreased Cdk2
concentrations in the nucleus that correlated with an
increase in Cdk2 binding to p27 in the cytoplasm
(Fig. 4b). Interestingly, rapamycin alone had little effect on
Cdk2 localization or Cdk2 binding to p27; however,
rapamycin potentiated a TGF-β1-induced decrease in
nuclear concentrations of Cdk2 that coincided with
increased binding of Cdk2 to primarily cytoplasmic, but
also nuclear, p27. These results are consistent with our
Available online http://breast-cancer-research.com/content/6/2/R130
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Figure 4
Cdk2 relocalization to the cytoplasm correlates with increased binding to cytoplasmic p21 and p27. (a) Crude MDA-MB-231 cytoplasmic (C) or
nuclear (N) extracts (Crude ext.) from cells treated as in Fig. 1 were subjected to immunoblot (IB) analysis with antibodies specific for Cdk2, p27,
or p21 (top panel), or immunoprecipitated with a Cdk2 antibody or antibody from preimmune rabbit IgG (Rab. IgG), and the immunoprecipitates
(Cdk2 IP) were probed with antibodies specific for Cdk2, p27, or p21 (bottom panel). (b) NMuMG cytoplasmic or nuclear extracts from cells
treated as in Fig. 1 were subjected to immunoprecipitation with Cdk2 antibody or preimmune rabbit IgG, and the immunoprecipitates were probed
with antibodies specific for Cdk2, Cdk2 phosphorylated on Tyr15 (P-Tyr15–Cdk2), Cdk2 phosphorylated on Thr160 (P- Thr160-Cdk2), p27, or p21.
Cont., control; Rapa., 100 nM rapamycin; T + R, 10 ng/ml transforming growth factor-β1 plus 100 nM rapamycin. LC, immunoglobulin light chain;
HC, immunoglobulin heavy chain.
Figure 3
p21 and p27 are localized primarily to the cytoplasm of NMuMG, MDA-MB-231, HMEC, and HaCaT cells. The cytoplasmic (C) and nuclear (N)
subcellular fractions prepared in Fig. 1a were analyzed by immunoblot with antibodies specific for p27 or p21. HIRA served as a marker for the
nucleus and Raf was used as a marker for the cytoplasm. Cont., control; T + R, 10 ng/ml TGF-β1 plus 100 nM rapamycin; HMEC, primary human
mammary epithelial cells.previous report that TGF-β1 and rapamycin cooperate to
induce p27 binding to Cdk2 [20], but extend these obser-
vations by demonstrating that binding of Cdk2 to cytoplas-
mic p27 and p21 coincides with decreased nuclear Cdk2
concentrations.
We hypothesized that the phosphorylation state of Cdk2
at activating or inhibitory sites might differ between the
nucleus and the cytoplasm. To test this hypothesis we
examined Cdk2 phosphorylation at the inhibitory phospho-
rylation site, Tyr15, and on the activating phosphorylation
site, Thr160, using phosphorylation state-specific antibod-
ies (Fig. 4b). Although concentrations of nuclear Cdk2
were quite low in the NMuMG cells treated with
TGF-β1 + rapamycin, concentrations of phospho-Tyr15
Cdk2 were decreased only slightly, indicating that the stoi-
chiometry of phosphorylation of nuclear Cdk2 on the
inhibitory site, Tyr15, was increased by treatment with
TGF-β1 + rapamycin. Similarly, the amount of p27 binding
to nuclear Cdk2 was also increased in NMuMG cells
treated with TGF-β1 + rapamycin. Taken together, these
results suggest that TGF-β1 and rapamycin cooperate to
inhibit the activity of nuclear Cdk2 through several mecha-
nisms including decreasing the total concentration of
nuclear Cdk2, increasing the stoichiometry of phosphory-
lation of nuclear Cdk2 on the inhibitory site, Tyr15, and
increasing the stoichiometry of binding of p27 to nuclear
Cdk2.
TGF-β β and rapamycin cooperate to inhibit nuclear, but
not cytoplasmic, Cdk2 activity
To verify that TGF-β1 and rapamycin cooperate to inhibit
nuclear Cdk2 activity specifically, we prepared nuclear
and cytoplasmic extracts from NMuMG cells treated as in
Fig. 4. The extracts were immunoprecipitated with anti-
bodies specific for Cdk2 and subjected to immune-
complex kinase assays with histone H1 as the substrate.
Results were analyzed by phosphorimaging and
immunoblot analysis of the kinase reactions (Fig. 5). Inter-
estingly, treatment with TGF-β1 preferentially inhibited
cytoplasmic Cdk2 activity while having little effect on
nuclear Cdk2 activity. Rapamycin weakly inhibited cyto-
plasmic Cdk2 activity and increased nuclear Cdk2 activity.
Strikingly, treatment with TGF-β1 + rapamycin inhibited
cytoplasmic Cdk2 activity to a similar extent to that of
TGF-β1 alone, but inhibited nuclear Cdk2 activity much
more potently than TGF-β alone.
It is interesting that neither TGF-β nor rapamycin alone
exhibited a strong inhibitory effect on soluble nuclear
Cdk2 activity, whereas together they strongly inhibited
soluble nuclear Cdk2 activity. Comparison of Figs 4b and
5 indicates that this cooperative behavior results from a
combination of effects. First, rapamycin potentiates the
TGF-β-induced decrease in soluble nuclear Cdk2 concen-
trations. Rapamycin alone has little effect on Cdk2 local-
ization. Second, although the concentration of soluble
nuclear Cdk2 is significantly lower in cells treated with
TGF-β + rapamycin relative to TGF-β-treated cells, the
concentration of Tyr15-phosphorylated Cdk2 is similar in
both treatments. Rapamycin alone has no effect on the
degree of Cdk2 phosphorylation on Tyr15. This suggests
that rapamycin increases the stoichiometry of soluble
nuclear Cdk2 phosphorylation on its inhibitory site, Tyr15,
in the context of TGF-β treatment. It is unclear how
rapamycin alone stimulates soluble nuclear Cdk2 activity,
but it might result from increased phosphorylation of Cdk2
on its activating site, Thr160. Third, although the concentra-
tion of soluble nuclear Cdk2 is significantly lower in cells
treated with TGF-β + rapamycin relative to TGF-β-treated
cells, the amount of p27 that coimmunoprecipitates with
Cdk2 is actually higher. Rapamycin alone has no effect on
the binding of p27 to soluble nuclear Cdk2. This suggests
Breast Cancer Research    Vol 6 No 2 Brown et al.
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Figure 5
Transforming growth factor-β (TGF-β) and rapamycin cooperate to
inhibit nuclear Cdk2 activity specifically. NMuMG cytoplasmic (C) or
nuclear (N) extracts from cells treated as in Fig. 1 were subjected to
immunoprecipitation (IP) with anti-Cdk2 antibody or antibody from
preimmune serum (Rab. IgG) as in Fig. 4. The immunoprecipitates
were subjected to immune-complex kinase assays with histone H1 as
the substrate. The kinase reactions/immunoprecipitates were analyzed
by phosphorimaging (histone H1 kinase assay) and by immunoblotting
(IB) with antibodies specific for Cdk2, p21, or p27. The bar graph in
the lower panel is a quantification of the histone H1 kinase assays.
Cont., control; T, 10 ng/ml TGF-β1; R, 100 nM rapamycin.that rapamycin increases the stoichiometry of binding of p27
to soluble nuclear Cdk2 in the context of TGF-β treatment.
Discussion
It has long been thought that the cyclin-dependent kinases
Cdk2 and Cdk4/Cdk6 have essential and unique roles in
regulating cell division. This presumption was weakened
by the observation that cyclin D1 deficiency is rescued by
a knockin of cyclin E [27]. More recently it was shown that
mice lacking cyclin E [28] or Cdk2 [29,30] are viable.
Additionally, several cancer cell lines proliferate normally in
the absence of Cdk2 [31]. These observations call into
question the relevance of Cdk2 inhibition by
TGF-β + rapamycin. However, it should be pointed out
that several cancer cell lines are arrested in the cell cycle
by the overexpression of dominant-negative Cdk2 or p27
[31]. Furthermore, cells lacking cyclin E are relatively resis-
tant to oncogenic transformation [28], and cells lacking
Cdk2 exhibit increased contact inhibition and delayed
entry into S phase [30]. It was proposed [28] that a low
cyclin-dependent kinase activity might be required for
normal cell proliferation, but that a higher cyclin-depen-
dent kinase activity might be required for oncogenic trans-
formation. Thus, even if Cdk2 is not absolutely required for
cell proliferation it could serve as a central target of
growth inhibitory, tumor suppressive pathways involved in
preventing uncontrolled cell proliferation.
We propose that in addition to these considerations con-
cerning Cdk2 kinase activity, the role of Cdk2 in cell cycle
progression must also take into account the biological
effects of regulated changes in the subunit composition of
Cdk2 complexes and changes in the intracellular localiza-
tion of Cdk2 and the components of Cdk2 complexes. We
have previously demonstrated that TGF-β and rapamycin
cooperate to inhibit Cdk2 activity and that this parallels
changes in the subunit composition of Cdk2 complexes
[20]. Here we present data indicating that Cdk2 function
might also be regulated by its intracellular localization and
that Cdk2 intracellular localization is linked with changes
in the subunit structure of Cdk2 complexes. In short, these
results suggest that TGF-β and rapamycin together regu-
late Cdk2 function in mammary epithelial cells through a
novel mode involving changes in Cdk2 intracellular local-
ization, and that in some cell types p21 and p27 might act
not only to inhibit Cdk2 directly but also to control Cdk2
intracellular localization and access to substrates.
Cdk2 is often assumed to reside primarily in the nucleus;
however, several reports indicate that Cdk2 localization is
dynamically regulated. Serum deprivation induces Cdk2
localization to the cytoplasm, and it was concluded that
serum-induced Cdk2 relocalization from the cytoplasm to
the nucleus overcomes the primary barrier to Cdk2 activa-
tion and the exit of cells from quiescence [32]. Similarly,
the ability of human cytomegalovirus infection to drive the
proliferation of serum-deprived or contact-inhibited cells
correlates with Cdk2 translocation from the cytoplasm into
the nucleus [33]. More recently it was shown that vitamin
D induces Cdk2 relocalization to the cytoplasm [34].
Cdk2 localization to the cytoplasm represents an effective
mechanism for inducing growth arrest because several
proteins that are intimately involved in cell proliferation are
localized predominantly to the nucleus and are substrates
for Cdk2-dependent phosphorylation. These proteins
include HIRA [21], p220NPAT [24], BRCA1 [22], and
nucleophosmin [25]. Cyclin A–Cdk2 complexes promote
DNA replication in part through the phosphorylation of
nuclear Cdc6, resulting in Cdc6 export from the nucleus
and subsequent degradation [23]. Further, the pocket pro-
teins Rb, p107, and p130 exist at least partly in the
nucleus, and Cdk2 regulates E2F-dependent transcription
through the phosphorylation of the pocket proteins.
Despite the importance of Cdk2 localization in regulating
cell proliferation, little is known about the mechanisms
controlling the subcellular targeting of Cdk2.
Previously we showed [20] that cell cycle arrest induced
by TGF-β + rapamycin results from Cdk2 inhibition due to
increased p21 and p27 binding to Cdk2. The observa-
tions presented here extend these observations by
showing that, in addition to directly binding and inhibiting
Cdk2, cytoplasmically localized p21 and p27 might also
act as targeting subunits to sequester Cdk2 away from
nuclear targets such as Rb. The data in this study suggest
that the mechanism behind Cdk2 relocalization probably
involves p21 and p27 because decreases in nuclear Cdk2
concentrations correlate with increased binding of Cdk2
to cytoplasmic p21 and p27. Further, rapamycin potenti-
ates TGF-β1-induced Cdk2 translocation in parallel with
the potentiation of Cdk2 binding to cytoplasmic p21 and
p27. The observation that TGF-β1 and rapamycin together
induce p27 binding to Cdk2 in both the nucleus and the
cytoplasm suggests that increased Cdk2 binding to p27
is independent of intracellular localization and suggests
that Cdk2 relocalization to the cytoplasm results from
increased binding of Cdk2 to the predominantly cytoplas-
mic p27.
Immunofluorescence microscopy studies indicate that
some Cdk2 is still present in the nucleus after TGF-β
treatment, but nuclear extracts from TGF-β-treated cells
contain very little Cdk2. To address this apparent discrep-
ancy, cell pellets remaining after the nuclear extraction
procedure were extracted by boiling in Laemmli SDS
sample buffer and the resulting extracts were subjected to
immunoblot analysis. These experiments indicated that in
both untreated and TGF-β-treated cells Cdk2 exists in the
nucleus in an insoluble form that can be extracted by SDS
(data not shown). Thus, two pools of nuclear Cdk2 exist, a
soluble nuclear fraction and an insoluble nuclear fraction.
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Our results indicate that the soluble nuclear Cdk2 fraction
is the most relevant target of TGF-β and rapamycin with
respect to Rb dephosphorylation and cell cycle arrest
induced by TGF-β and rapamycin.
Like Cdk2, p21 and p27 are generally considered to be
nuclear proteins; however, several reports indicate that
p21 and p27 distribution between the nucleus and the
cytoplasm is regulated. p27 intracellular localization is
controlled by several phosphorylation sites, including
Ser10 [35–37], Thr157 [38–40], and Thr198 [41,42]. Phos-
phorylation of Ser10 induces p27 export to the cytoplasm
and stabilizes the protein, and the phosphorylation status
of this residue does not alter the intrinsic ability of p27 to
inhibit Cdk2 activity [35]. Thr157 phosphorylation induces
the cytoplasmic localization of p27; however, Thr157,
unlike Ser10, is not conserved in murine p27. Therefore
Thr157 phosphorylation cannot explain the cytoplasmic
localization of p27 observed in NMuMG cells. Phosphory-
lation of p27 on Thr198 promotes p27 binding to 14-3-3
proteins and localization to the cytoplasm [41,42].
On the basis of the assumption that Cdk2 is predomi-
nantly nuclear, it has been presumed that cytoplasmic p21
and p27 are not involved in regulating the cell cycle. In
fact it has been proposed that p21 and p27 have different
functions in the cytoplasm and might act as cytoplasmic
oncoproteins [43,44], in part by inhibiting apoptosis. A
recent report [45] suggests that p27 in the cytoplasm
interacts with F-actin and regulates cell motility. Although
p21 and p27 probably have different functions in the cyto-
plasm as opposed to the nucleus, our results indicate that
cytoplasmic p21 and p27 bind Cdk2 and might in fact
serve to control Cdk2 localization in a regulated manner.
These results are consistent with those in a recent report
[46] that identified an isoform of p27, p27(Kip1R), that
was retained in the cytoplasm but inhibited cell prolifera-
tion in a manner similar to the more extensively studied
p27 isoform, p27(Kip1). Thus, categorizing p21 and p27
as tumor suppressors when localized to the nucleus, and
oncogenic when localized to the cytoplasm, is probably an
oversimplification. Further studies are warranted to deter-
mine the precise cellular functions of cytoplasmically local-
ized p21, p27, and Cdk2.
Conclusion
Our results demonstrate for the first time that TGF-β1 reg-
ulates Cdk2 intracellular localization in mammary epithelial
cells and human keratinocyes and that this process is
involved in potent and specific inhibition of nuclear Cdk2
activity that results in the dephosphorylation of nuclear Rb.
Regulation of Cdk2 localization by TGF-β1 and
TGF-β1 + rapamycin correlates with increased Cdk2
binding to cytoplasmic p21 and p27, in the absence of
changes in total p27 concentrations. These results
suggest that p21 and p27 not only serve as Cdk2
inhibitory proteins but might also serve as Cdk2 intracellu-
lar targeting subunits. Studies are currently under way to
determine the precise mechanisms by which TGF-β1 reg-
ulates the intracellular localization and association of Cdk2
with p21 and p27.
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